Gamida Cell Ltd. (GMDA)
Market Cap | 110.38M |
Revenue (ttm) | n/a |
Net Income (ttm) | -87.41M |
Shares Out | 74.58M |
EPS (ttm) | -1.28 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,136,408 |
Open | 1.36 |
Previous Close | 1.32 |
Day's Range | 1.33 - 1.53 |
52-Week Range | 1.10 - 4.72 |
Beta | 1.66 |
Analysts | Buy |
Price Target | 12.65 (+754.73%) |
Earnings Date | Mar 27, 2023 |
About GMDA
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Ho... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for GMDA stock is "Buy." The 12-month stock price forecast is $12.65, which is an increase of 754.73% from the latest price.
News

Gamida Cell Announces Changes to Board of Directors
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum. The Board...

Gamida Cell Announces the Date of Its Fourth Quarter and Full Year 2022 Financial Results and Webcast
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live...

Gamida Cell to Present Corporate Highlights at the Oppenheimer 33rd Annual Healthcare Conference
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Off...

Data Presented on Gamida Cell's Omidubicel, GDA-201 at the 2023 Tandem Meetings of ASTCT and CIBMTR
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

Gamida Cell (GMDA) Upgraded to Buy: Here's Why
Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gamida Cell Announces Closing of $25 Million Financing With Highbridge
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious disease...

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, toda...

Gamida Cell Provides Regulatory Update on Omidubicel
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, to...

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, toda...

Gamida Cell to Present Corporate Highlights at the Jefferies London Healthcare Conference
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

Gamida Cell Announces the Date of Its Third Quarter 2022 Financial Results and Webcast
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

GDA-501, NAM enabled NK Cell Therapy, Demonstrates Promising Antitumor Activity Against HER2+ Cancers
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

Gamida Cell Announces Omidubicel Data To Be Presented as an Oral Presentation at 64th ASH Annual Meeting
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd.

Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today ...

Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases,...

Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases,...

Gamida Cell Announces Launch of Public Offering of Ordinary Shares
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases,...

Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases,...

Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting
BOSTON--(BUSINESS WIRE)-- #BloodCancerAwarenessMonth--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and o...

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today ...

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease...